Nightingale Health

Nightingale Health's mission is to build sustainable healthcare and reduce health inequalities. The company states that it has developed the world's most advanced health check for the health industry, providing risk detection for multiple chronic diseases from a single blood sample, scalable to entire populations at low cost and able to replace many current risk assessments. It operates globally with a parent company in Finland and seven subsidiaries in countries such as Japan, the United States, Singapore, and the United Kingdom, serving customers in more than 25 countries in the healthcare and medical research sectors. Its technology has been used in health initiatives such as the UK Biobank, and the company reports over 600 peer-reviewed publications validating the technology. In 2025, Nasdaq Helsinki approved its listing application on the Main Market, with trading in B shares commencing on 19 March 2025 under the trading code HEALTH, and trading in B shares and ADRs beginning on the OTCQX International Market in the US on 21 March 2025.

Nightingale Health states that its mission is to build sustainable healthcare and reduce health inequalities, and that it has developed the world's most advanced health check for the health industry, providing risk detection for multiple chronic diseases from a single blood sample. The company operates globally with a parent company in Finland and seven subsidiaries in countries such as Japan, the United States, Singapore, and the United Kingdom, and has customers in more than 25 countries in the healthcare and medical research sectors. Its technology is used in health initiatives such as the UK Biobank, and over 600 peer-reviewed publications validate the technology. In 2024, the company announced collaborations with Kaiser Foundation, ZOE, Boston Heart Diagnostics, 23andMe, and Phenome Health; it also acquired all intellectual property assets of the Velvet blood collection device and secured its position as the sole provider of a fully integrated remote health check, and its new laboratory in the UK started operating. In 2025, Nasdaq Helsinki approved its listing application on the Main Market, and trading in the B shares commenced on 19 March 2025 with the trading code HEALTH; trading in its B shares and ADRs began on the OTCQX International Market in the US on 21 March 2025.

The most advanced health check for the health industry; the gold standard 'omics for the research community.

• Health Check

  The most advanced health check for the health industry.

• Remote Health Check

  The most advanced remote health check for the health industry; delivers the industry's broadest panel of blood markers with clinical grade quality, including around 30 well-known blood markers such as cholesterol levels, extended lipid profile, fatty acids, amino acids, sugar metabolism, and inflammation.

• Multiomics Hub

  Brings together multiple 'omics in one seamless workflow; from a single blood sample, it delivers comprehensive metabolic data with an optional proteomics add-on.

1. 1Building better healthcare for everyone. | Nightingale Healthnightingalehealth.com
2. 2About us | Nightingale Healthnightingalehealth.com
3. 3For Research | Nightingale Healthnightingalehealth.com